Ahmedabad-based pharma major Cadila Healthcare on Friday informed the stock exchanges that no observations were issued by the US Food and Drugs Administration (USFDA) against its topicals manufacturing plant at Changodar.
The plant was inspected by the USFDA between April 3 to April 7. According to a notice to the BSE no observation (483) was issued. The company has filed 17 products with the USFDA from the site. Shares of Cadila Healthcare were up 1.5 per cent to Rs 454.85 a share in day's trade on the BSE.
Earlier, in February, the company's Moraiya unit too did not receive any observations from the USFDA.